An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Completed at 13 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 6th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 34th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Austria, France and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, France and 4 more countries
Ages 6 mo–17 yrs
AbbVie · Sites in India
Ages 18+
AbbVie · Sites in Colombia
Ages 18+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 7 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is close to the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 62 across the 32 interventional studies, 113 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
5 of the studies in Leukemia, Myeloid, Acute by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05587049AbbVieA Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | 2026-11 |
| NCT04086264AbbVieIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | 2027-02 |
| NCT03987958AbbVieA Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) | 2027-07 |
| NCT07044687AbbVieStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for intensive chemotherapy in Greece.
Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled.
Around 100 participants will be enrolled in the study in approximately 15 sites in Greece.
Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 30 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 30 months.
Adult participants with acute myeloid leukemia (AML) treated with venetoclax per approved local label in Greece.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated with Venetoclax in accordance with approved local label.
Percentage of Participants Achieving Overall Survival (OS)
OS is defined as the time from treatment initiation to death from any cause.
Time frame: Up to 30 Months
Percentage of Participants Achieving Composite Complete Remission
Composite complete remission is defined as the proportion of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi).
Time frame: Up to 30 Months
Total Time of Treatment with Venetoclax Combination Therapy
The total time of treatment with venetoclax combination therapy.
Time frame: Up to 30 Months
Time to Transfusion Independence
Total duration of transfusion independence is defined as the period of at least 56 days with no Red Blood Cell (RBC) or platelet transfusion between the first dose of study drug and the last dose of study drug plus 30 days.
Time frame: Up to 30 Months
Post Baseline RBC and Platelet Transfusion Independence Rate
Post baseline RBC and platelet transfusion independence rate will be calculated as the proportion of participants who achieved RBC and platelet, respectively, transfusion independence post baseline.
Time frame: Up to 30 Months
Change from Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Considered Minimally Clinical Important
The EQ-5D-5L is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments.
Time frame: Up to 30 Months
Treatment Patterns Venetoclax in Combination with Hypomethylating Agents (HMAs)
Treatment patterns defined by the proportion of participants treated with venetoclax in combination with HMAs (dosing with venetoclax and any modifications/interruptions/titrations, type and dosing of each HMA, frequency of response assessment, cycle length, dosing, concomitant medications, etc).
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Number of Transfusions (Red Blood Cell [RBC] or Platelets) Received during First-line Treatment in an Outpatient Setting
Healthcare resource utilization as the number of transfusions (red blood cell \[RBC\] or platelets) received during first-line treatment in an outpatient setting.
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Number of Hospitalizations during First-line Treatment
Healthcare resource utilization as the number of hospitalizations during first-line treatment.
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Number of Intensive Care Unit (ICU) Admissions during First-line Treatment
Healthcare resource utilization as the number of intensive care unit (ICU) admissions during first-line treatment.
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Number of Visits in a Private Healthcare Practitioner
Healthcare resource utilization as the number of visits in a private healthcare practitioner.
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Name of Relevant Medication due to Infections (Antibiotics or Other)
Healthcare resource utilization as the name of relevant medication due to infections (antibiotics or other).
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Dosing Scheme of Relevant Medication due to Infections (Antibiotics or Other)
Healthcare resource utilization as the dosing scheme of relevant medication due to infections (antibiotics or other).
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Number of Laboratory Tests
Healthcare resource utilization as the number of laboratory tests.
Time frame: Up to 30 Months
Healthcare Resource Utilization as the Type of Laboratory Tests
Healthcare resource utilization as the type of laboratory tests.
Time frame: Up to 30 Months
Plan to share: Undecided
Ran from May 2022 to primary completion in May 2026, 48 months.
Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 154. This study's 48 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → May 2026 and completion Dec 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.